Fosamax and Osteonecrosis of the Jaw: Understanding the Risk and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Drug Safety Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatments. Within this broad context, the dissemination of knowledge about pharmaceuticals and their potential side effects has been a key focus, helping patients and providers make informed decisions. As this heritage evolved, it increasingly emphasized the importance of scrutinizing specific drug exposures and their long-term implications for patient safety. Transitioning from this general health framework, a more targeted concern emerges regarding occupational and environmental exposures. In particular, the focus narrows to the relationship between bisphosphonate medications, such as Fosamax, and the risk of osteonecrosis of the jaw. This pivot moves the discussion from broad health education to a specific exposure scenario, where the question of causation becomes paramount. The shift requires examining how prolonged use of such agents, often prescribed for bone density issues, may correlate with adverse outcomes in the oral cavity. This transition underscores the need to evaluate risk factors and exposure durations without delving into mechanistic details, maintaining a neutral stance on the underlying biological processes. The goal is to reframe the inquiry from general health awareness to a precise investigation of drug exposure and its potential consequences.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the general health framework, we now turn to a specific and serious adverse event associated with bisphosphonate therapy: osteonecrosis of the jaw (ONJ). Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ is a recognized adverse effect associated with bisphosphonate use, including Fosamax. It is characterized by exposed necrotic bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Clinical Presentation and Diagnosis of ONJ

The clinical presentation of ONJ involves delayed healing of the jawbone after dental procedures, often with exposed bone that may become infected. Diagnosis is typically based on clinical examination and imaging, with a focus on identifying necrotic bone in the oral cavity. The condition can be painful and may lead to significant morbidity, including difficulty eating and speaking. Multiscale characterization of jawbone tissue has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research underscores the unique biological environment of the jawbone, which may contribute to its susceptibility to ONJ.

Mechanistic Pathways Linking Fosamax to ONJ

Mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast-mediated bone resorption. Bisphosphonates like alendronate accumulate in bone tissue, particularly at sites of high turnover, such as the jaw. This accumulation can suppress normal bone remodeling, leading to microdamage accumulation and reduced ability to repair minor injuries, such as those from dental procedures. The resulting avascular necrosis is thought to be exacerbated by local infection, inflammation, and impaired blood supply.

Risk Factors and Duration of Exposure

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, population-level data indicate that risk is cumulative. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This suggests that while the absolute risk is small, it increases with prolonged exposure.

Warnings and Labeling for Fosamax

Adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's prescribing information. The label includes a specific warning under Section 5.4, "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Additionally, the label advises discontinuing use if severe symptoms develop, and notes that most patients had relief of symptoms after stopping, though a subset had recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations for Affected Patients

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and the development of ONJ, as well as ruling out other potential causes such as cancer, radiation therapy, or other medications. The label identifies known risk factors, including invasive dental procedures, cancer diagnosis, and concomitant therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ while on Fosamax, the label recommends discontinuing the drug if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may be reduced by discontinuing bisphosphonate treatment prior to invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Summary of Evidence and Clinical Implications

In summary, the evidence supports a causal association between Fosamax use and ONJ, with risk increasing with duration of exposure. The drug's label provides warnings and guidance for risk mitigation, including discontinuation before dental procedures and monitoring for symptoms. Patients and clinicians should weigh the benefits of fracture reduction against the rare but serious risk of ONJ, particularly with long-term use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that can cause osteonecrosis of the jaw (ONJ), a condition where the jawbone becomes exposed and fails to heal. The risk increases with longer duration of use, especially after 2-3 years. The drug's label includes warnings about this risk and recommends discontinuation before invasive dental procedures.

How common is ONJ in patients taking Fosamax?

The absolute risk of ONJ in osteoporosis patients taking Fosamax is low, approximately 0.05% after 5 years of use. However, the risk increases with duration: threefold higher after 2-3 years and eightfold higher after 10 years compared to past use. Risk diminishes after discontinuation.

What are the risk factors for developing ONJ while on Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. The risk also increases with longer exposure to bisphosphonates.

What should I do if I develop jaw symptoms while taking Fosamax?

If you develop symptoms such as jaw pain, swelling, or exposed bone, consult your healthcare provider immediately. The drug label recommends discontinuing Fosamax if severe symptoms develop. Most patients experience relief after stopping, but a subset may have recurrence if rechallenged.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.